Canadian Manufacturing

Liminal BioSciences sells plasma-derived therapeutics manufacturing facility

The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments.

July 12, 2021  by CM Staff

LAVAL and CAMBRIDGE — Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, announced on Jul. 12 that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. The manufacturing facility is operated through Liminal BioSciences’ subsidiary, Prometic Bioproduction Inc.

The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher by its subsidiary, Prometic Biotherapeutics Inc., which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT. PBT is the holder of the biological license application for Ryplazim® (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.

Liminal BioSciences is a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases of unmet medical need, primarily related to fibrosis, including respiratory, liver and kidney diseases.

Advertisement

Print this page

Related Stories